Discovery of the overexpressed EGFR due to EGFR high polysomy and gene amplification in HNSCC led to the development and application of EGFR-specific cetuximab-based immunotherapy for HNSCC treatment [18], [19]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.